Fracture Recovery for Returning to Duty (Teriparatide STRONG)
Status:
Not yet recruiting
Trial end date:
2024-09-25
Target enrollment:
Participant gender:
Summary
FORTEO (teriparatide [rDNA origin]; Eli-Lilly, Indiana, USA) is an injectable synthetic
recombinant human parathyroid hormone analog that is commonly used to treat people with
osteoporosis. In the current investigation this drug will be tested to evaluate its efficacy
to accelerate bone healing and decrease the convalescence time of US Army Basic Trainees who
have sustained a diaphyseal tibial stress fracture (DTSF). Investigators from the University
of South Carolina will collaborate with military personnel to perform a prospective,
randomized, double-blind, placebo-controlled study at Fort Jackson, SC.